140 results
6-K
EX-99.1
BLU
Bellus Health Inc
2 Jun 23
Notice of Annual and Special Meeting of Shareholders
4:25pm
of the President and Chief Executive Officer, the objectives of the President and Chief Executive Officer and the assessment of whether and to what extent … annual meeting, as well as recommendations with respect to the process for board, committee and director assessment. In identifying potential candidates
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
of Directors’ assessment of the current and anticipated future opportunities and risks associated with the business, operations, assets, financial … of, and consideration to be received by, holders of Company Equity Awards under the Arrangement;
the Board of Directors’ assessment of the Parent’s ability
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
to arrange for and scale up the manufacturing of camlipixant to reach commercial scale, if approved;
our estimates and assessment of the potential
6-K
EX-99.2
BLU
Bellus Health Inc
27 Apr 23
Material Change Report
6:04am
filed with or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment … to any waiver or extension in respect of a period within which an assessment or reassessment of material Taxes may be issued; (F) request any extension
6-K
EX-99.2
BLU
Bellus Health Inc
30 Mar 23
Notice of Annual and Special Meeting of Shareholders
11:22am
and Chief Executive Officer and the assessment of whether and to what extent such objectives are met. The members of the Compensation Committee … to the process for board, committee and director assessment. In identifying potential candidates, the Committee seeks to put forward individuals
6-K
EX-99.1
9dl pc4ctgtwz
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.2
4ydprmt xg
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
7186kb
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
4fd5na
14 Nov 22
Open Market Sale Agreementsm
5:19pm
6-K
EX-99.1
1ec7e
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
F-10
1i1a02t q6
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.2
drcug86b
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm
SUPPL
u5kuh9p0dbnz
15 Jul 22
Supplemental materials (foreign)
7:01am
6-K
EX-99.2
758x7nl6
14 Jul 22
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
4:46pm
SUPPL
zm39vqd2xrplqmg
13 Jul 22
Supplemental materials (foreign)
5:01pm
6-K
EX-99.2
6onj07lum km3hgbnt
11 May 22
Condensed Consolidated Interim Financial Statements of
5:05pm
6-K
EX-99.1
emsvrdu9v9db3av
2 May 22
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
7:00am
6-K
EX-99.2
il9bw5 a6p
7 Apr 22
Notice of Annual Meeting of Shareholders
9:01am
6-K
EX-99.1
h6ei66oin kylb1
5 Apr 22
Current report (foreign)
4:07pm
40-F
y8eseo0g81
23 Feb 22
Annual report (Canada)
5:20pm